COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS)
Napo Pharmaceuticals presents statistically significant results of crofelemer in breast cancer patients for prophylaxis of CTD at SABCS. Study highlights impact of diarrhea in cancer treatment -
-
-
COMMUNIQUÉ DE PRESSE
Poster Presentation Describing the Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients to Take Place December 11, 2024 at San Antonio Breast Cancer Symposium (SABCS)
Jaguar Health's Napo Pharmaceuticals to present data on crofelemer in breast cancer patients at SABCS 2024. Additional analyses ongoing. Patient advocacy program also announced -
-
-
COMMUNIQUÉ DE PRESSE
U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health’s Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins
Jaguar Health's crofelemer undergoing clinical studies for rare diseases SBS-IF and MVID in multiple regions; Orphan Drug Designation granted by FDA and EMA
